Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to Liposomes


Authors: D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, U. D'Oro, S. Woods, C.W. Roberts, Y. Perrie, and R. Adamo

Journal: Journal of Controlled Release

DOI: 10.1016/j.jconrel.2020.04.001

Publication - Abstract

April 02, 2020

Abstract

Although the well-known Toll like receptor 9 agonist CpGODN has shown promising results as vaccine adjuvant in preclinical and clinical studies, its in vivo stability and potential systemic toxicity remain a concern. In an effort to circumvent these issues, different strategies have been employed to increase its stability, localise action and reduce dosage. These include conjugation of CpGODN with proteins or encapsulation/adsorption of CpGODN into/onto liposomes, and have resulted in enhanced immunopotency compared to co-administration of free CpGODN and antigen.

Here, we designed a novel delivery system of CpGODN based on its conjugation to serve as anchor for liposomes. Thiol-maleimide chemistry was utilised to covalently ligate the Group B Streptococcus (GBS) GBS67 protein antigen with the CpGODN TLR9 agonist. This treatment did not alter protein's ability to be recognised by specific antibodies or the CpGODN to function as a TLR9 agonist. Due to its negative charge, the protein conjugate readily electrostatically bound cationic liposomes composed of 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol and dimethyldioctadecylammonium bromide (DDA). The novel cationic liposomes-protein conjugate complex (GBS67-CpGODN+L) shared similar vesicle characteristics (size and charge) compared to free liposomes but exhibited different structure and morphology. Following intramuscular immunisation, GBS67-CpGODN+L formed a vaccine depot at the injection site and induced a remarkable increase of functional immune responses against GBS compared to the simple co-administration of GBS67, CpGODN and liposomes. This work demonstrates that the conjugation of CpGODN to GBS67 in conjunction with adsorption on cationic liposomes, can promote co-delivery leading to the induction of a multifaceted immune response at low antigen and CpGODN doses. Our findings highlight the potential for harnessing the immunostimulatory properties of different adjuvants to develop more effective nanostructure-based vaccine platforms.

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Effect of Complexing Lipids on Cellular Uptake and Expression of Messenger RNA in Human Skin Explants

A.K.. Blakney, P. Deletic, P.F. McKay, C.R. Bouton, M. Ashford, R.J. Shattock and A. Sabirsh

mRNA was formulated in lipoplexes with ionizable, cationic or zwitterionic complexing lipids.

Cell populations in human skin were analyzed for RNA uptake and expression over 72 h.

Adipocytes exhibit...

Read More


Publication - Abstract

Humanized Biomimetic Nanovesicles for Neuron Targeting

A. Zinger, C. Cvetkovic, M. Sushnitha, T. Naoi, G. Baudo, M. Anderson, A. Shetty, N. Basu, J. Covello, E. Tasciotti, M. Amit, T. Xie, F. Taraballi, and R. Krencik

In an article written by Zinger et al. 2021 from the Center for Musculoskeletal Regeneration at the Houston Methodist Research Institute, the challenge of reproducible and scalable therapeutic drug delivery with high cell specificity to neural cells was investigated through analy...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.